Total Payments
$366,719
2024 Payments
$11,679
Companies
27
Transactions
528
Medicare Patients
1,263
Medicare Billing
$142,776
Payment Breakdown by Category
Other$200,026 (54.5%)
Research$78,046 (21.3%)
Travel$44,713 (12.2%)
Consulting$36,042 (9.8%)
Food & Beverage$7,875 (2.1%)
Education$16.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $199,066 | 122 | 54.3% |
| Unspecified | $78,046 | 60 | 21.3% |
| Travel and Lodging | $44,713 | 178 | 12.2% |
| Consulting Fee | $36,042 | 28 | 9.8% |
| Food and Beverage | $7,875 | 135 | 2.1% |
| Honoraria | $875.00 | 1 | 0.2% |
| Grant | $85.45 | 2 | 0.0% |
| Education | $16.59 | 2 | 0.0% |
Payments by Type
General
$288,673
468 transactions
Research
$78,046
60 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $110,162 | 175 | $0 (2022) |
| Lilly USA, LLC | $89,562 | 107 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $34,945 | 33 | $0 (2021) |
| Eli Lilly and Company | $30,025 | 13 | $0 (2024) |
| Glenmark Pharmaceuticals Inc. | $24,676 | 9 | $0 (2017) |
| Circassia Pharmaceuticals Inc | $19,543 | 9 | $0 (2017) |
| PFIZER INC. | $18,477 | 15 | $0 (2024) |
| Allergan, Inc. | $17,083 | 44 | $0 (2021) |
| Lundbeck LLC | $5,682 | 15 | $0 (2020) |
| ModernaTX, Inc. | $4,410 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,679 | 35 | PFIZER INC. ($7,170) |
| 2023 | $14,766 | 26 | PFIZER INC. ($11,308) |
| 2022 | $19,748 | 17 | Lilly USA, LLC ($16,611) |
| 2021 | $17,835 | 17 | Teva Pharmaceuticals USA, Inc. ($6,000) |
| 2020 | $69,960 | 82 | Teva Pharmaceuticals USA, Inc. ($23,712) |
| 2019 | $122,358 | 195 | Lilly USA, LLC ($54,384) |
| 2018 | $55,001 | 98 | Amgen Inc. ($35,168) |
| 2017 | $55,371 | 58 | Glenmark Pharmaceuticals Inc. ($24,676) |
All Payment Transactions
528 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $66.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $634.80 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $381.74 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $160.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $124.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/03/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $7.42 | General |
| Category: PAIN | ||||||
| 10/08/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $122.44 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $198.23 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $123.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $60.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $47.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $24.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $24.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/17/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: IMMUNOLOGY | ||||||
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $328.95 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $265.53 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $81.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | Cash or cash equivalent | $77.97 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $24,676 | 9 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY | Eli Lilly and Company | $24,019 | 3 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $10,459 | 3 |
| An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | Circassia Pharmaceuticals Inc | $9,084 | 6 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $2,792 | 2 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI PASTEUR INC. | $1,636 | 11 |
| AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma | Regeneron Pharmaceuticals, Inc. | $1,149 | 9 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | Eli Lilly and Company | $1,131 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $902.25 | 1 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $711.00 | 3 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $451.00 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $451.00 | 2 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | Eli Lilly and Company | $430.32 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Oral Celecoxib | Dr.Reddy's Laboratories,Inc. | $104.77 | 3 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE | Eli Lilly and Company | $50.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 275 | 2,156 | $152,651 | $33,101 |
| 2022 | 9 | 305 | 2,187 | $147,159 | $35,635 |
| 2021 | 12 | 353 | 2,079 | $136,148 | $36,923 |
| 2020 | 10 | 330 | 2,451 | $136,110 | $37,118 |
Total Patients
1,263
Total Services
8,873
Medicare Billing
$142,776
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 193 | $67,909 | $15,982 | 23.5% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 13 | 630 | $28,800 | $6,952 | 24.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $9,240 | $2,408 | 26.1% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 20 | 750 | $14,250 | $2,244 | 15.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 60 | 99 | $11,979 | $1,951 | 16.3% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 18 | 238 | $5,692 | $1,502 | 26.4% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 16 | 177 | $10,797 | $1,421 | 13.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 11 | 12 | $2,184 | $337.15 | 15.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 36 | $1,800 | $302.82 | 16.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 117 | 189 | $62,945 | $16,215 | 25.8% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 17 | 780 | $32,715 | $9,768 | 29.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 75 | 109 | $13,189 | $2,124 | 16.1% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 18 | 689 | $13,091 | $2,046 | 15.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $5,280 | $1,452 | 27.5% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 24 | 167 | $10,187 | $1,438 | 14.1% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 15 | 185 | $4,230 | $1,176 | 27.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 15 | $3,472 | $1,006 | 29.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 13 | 41 | $2,050 | $409.67 | 20.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 109 | 180 | $52,020 | $16,103 | 31.0% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2021 | 14 | 630 | $24,300 | $7,667 | 31.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 28 | 28 | $12,344 | $3,535 | 28.6% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 22 | 674 | $12,806 | $2,162 | 16.9% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 66 | 93 | $11,253 | $2,102 | 18.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 24 | $4,776 | $1,611 | 33.7% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 18 | 216 | $4,752 | $1,486 | 31.3% |
About Dr. Gary Berman, M.D
Dr. Gary Berman, M.D is a Clinical & Laboratory Immunology healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609836121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Berman, M.D has received a total of $366,719 in payments from pharmaceutical and medical device companies, with $11,679 received in 2024. These payments were reported across 528 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($199,066).
As a Medicare-enrolled provider, Berman has provided services to 1,263 Medicare beneficiaries, totaling 8,873 services with total Medicare billing of $142,776. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical & Laboratory Immunology
- Location Minneapolis, MN
- Active Since 03/27/2006
- Last Updated 02/02/2010
- Taxonomy Code 207KI0005X
- Entity Type Individual
- NPI Number 1609836121
Products in Payments
- Aimovig (Biological) $93,576
- EMGALITY (Drug) $76,848
- AJOVY (Biological) $29,712
- NURTEC ODT (Drug) $15,859
- UBRELVY (Drug) $13,911
- VYEPTI (Biological) $5,557
- AJOVY (Drug) $4,941
- ZAVZPRET (Drug) $3,960
- Odactra (Biological) $1,399
- Dust mite (D. farinae) (Biological) $1,299
- MK-7264 (Drug) $1,185
- DUPIXENT (Biological) $1,149
- BOTOX (Drug) $375.00
- TEV-48125 (Biological) $188.89
- NUCALA (Biological) $70.85
- DUPIXENT (Drug) $46.85
- FASENRA (Drug) $44.51
- CINQAIR (Drug) $29.78
- DUPIXENT DUPILUMAB INJECTION (Biological) $28.12
- ALAIR (Device) $19.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical & Laboratory Immunology Doctors in Minneapolis
Dr. Hemalini Mehta, M.d, M.D
Clinical & Laboratory Immunology — Payments: $152,097
Clinical & Laboratory Immunology $152,097
Dr. Harold Kaiser, M.d, M.D
Clinical & Laboratory Immunology — Payments: $34,232
Clinical & Laboratory Immunology $34,232
Dr. Philip Halverson, M.d, M.D
Clinical & Laboratory Immunology — Payments: $11,334
Clinical & Laboratory Immunology $11,334
Dr. Richard Bransford, M.d, M.D
Clinical & Laboratory Immunology — Payments: $438.20
Clinical & Laboratory Immunology $438.20
Dr. Allan Stillerman, M.d, M.D
Clinical & Laboratory Immunology — Payments: $230.25
Clinical & Laboratory Immunology $230.25